MNs are synthesized from cross-linked hyaluronic acid (HA) and loaded with drug CpG oligonucleotide (TLR9 agonist) containing model immune regulation nanoparticles for cancer treatment in melanoma and cancer models. The gene discussed is TLR9; the disease is cancer.